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The microtubule-associated protein Tau (MAPT) is a major component of the pathogenesis of a wide variety of brain-damaging
disorders,known astauopathies. Theseinclude Alzheimer’s disease(AD),denoted as secondarytauopathy because oftheobligato-
rycombinationwithamyloidpathology.Inalltauopathies,proteinTaubecomesaberrantlyphosphorylated,adoptsabnormalcon-
formations, and aggregates into ﬁbrils that eventually accumulate as threads in neuropil and as tangles in soma. The argyrophilic
neuroﬁbrillary threads and tangles, together denoted as NFT, provide the postmortem pathological diagnosis for all tauopathies.
In AD, neuroﬁbrillary threads and tangles (NFTs) are codiagnostic with amyloid depositions but their separated and combined
contributions to clinical symptoms remain elusive. Importantly, NFTs are now considered a late event and not directly responsible
for early synaptic dysfunctions. Conversely, the biochemical and pathological timeline is not exactly known in human tauopathy,
but experimental models point to smaller Tau-aggregates, termed oligomers or multimers, as synaptotoxic in early stages. The
challengeistomolecularlydeﬁnetheseTau-isoformsthatcauseearlycognitiveandsynapticimpairments.Here,wediscussrelevant
studiesanddataobtainedinourmono-andbigenicvalidatedpreclinicalmodels,withtheperspectiveofTauasatherapeutictarget.
1.Introduction
It is no coincidence to begin this paper on protein Tau and
tauopathiesbyreferringtoAlzheimer’sdisease(AD),because
it is the most frequent tauopathy, albeit a “secondary” one.
More than hundred years after the ﬁrst documented case
of AD, the etiology of sporadic forms remains hitherto
unknown. Demographic changes, increased life expectancy
with a fast growing elderly population, lead us and all future
generations to the dramatic increase in the incidence and
prevalence of AD—described by some as “the pandemic of
the 21st century” [1].
The extracellular amyloid deposits, c.q. neuritic plaques
andcerebrovascularangiopathy,togetherwiththeintracellu-
lar neuroﬁbrillary threads and tangles (NFT) remain the key
pathological markers in AD brain. Nevertheless, the essential
basis of cognitive impairment is generally accepted to be
reducedsynaptic plasticity,evolvingintolossofsynapsesand
eventuallylossofneuronsonlyinlaterstages[2–5].Extensive
genetic and biochemical data have implicated the amyloid
peptides, the main components of the amyloid deposits, as
the central mediators of AD. The amyloid cascade hypo-
thesis, prevailing for more than two decades, stated that the
amyloid deposition is the initiating event of neuronal dys-
function and cell death in brain [6]. In familial AD-
cases, production of more and longer amyloid peptides, for
example, Aβ1–42, by abnormal proteolysis of the mem-
brane-bound amyloid precursor protein (APP) triggers a
pathologic cascade, years, or decades before the overt clini-
cal manifestations of the disorder [7–9]. By extension, a
similar pathogenic pattern is proposed in sporadic AD cases,
wherebyincreasedlevelsofsimilarorotheramyloidpeptides,
for example, Aβ1–38, Aβ1–43, pE3Aβ3-x among others, can
stem from deviating proteolysis, increased production, fail-
ing degradation, and ApoE-mediated elimination from the
brain.
The major—if not only—arguments that support the
amyloid hypothesis are genetic by nature [12]. The detection2 International Journal of Alzheimer’s Disease
of diﬀerent mutations in the gene coding for APP, but even
more so in the gene coding for presenilin-1 (PS1) is deﬁned
as causing early onset familial AD [12]. Conversely, overpro-
duction of amyloid peptides from mutant APP, alone or in
combination with mutant PS1 in transgenic mouse brain,
failed to cause appreciable tauopathy or neuronal degen-
eration. The question arose whether accumulating amyloid
peptides are indeed the real culprit for neurodegeneration
in AD. Recent neuroimaging studies demonstrated consider-
able amyloid deposits in the brain of a sizeable fraction, that
is, 15–30% depending on the study, of cognitively normal
individuals, whereas clinically diagnosed AD patients can
show no amyloid deposition by PET scan [13, 14]. These and
other observations have led to the modiﬁed amyloid hypo-
thesis, stating that not deposits but soluble toxic amyloid
speciesmustinitiateAD-pathology,andmoreover,thattauo-
pathy is essentially implicated [15].
For decades, the microtubule-associated protein Tau was
known as the main component of NFT, and although occu-
pying the number two spot on the list of proteins implicated
inAD,thefocusoftheﬁeldistraditionallyaimedonamyloid.
Long-standing observations, nevertheless, indicate that neu-
ronal tauopathy provides the closest pathological approxi-
mation of clinical defects observed during the life of AD
patients. The typical brain-regional occurrence and progres-
sionofTaupathologycorrelatestemporallyandspatiallywell
with neuronal and cognitive dysfunction [16, 17], with the
added weight of the correlation to CSF-levels of phosphory-
latedTau[18].Therefore,thecrucialquestionremainswhere
protein Tau should be placed in the amyloid cascade hypoth-
esis: downstream, at the same level or even upstream of
amyloid? Should we consider protein Tau as a by-stander of
the amyloid toxicity, as a mediator or even as a prime player,
and therefore preferred target? Only recently fundamental
scientist have gained more insight into how these two main
defects and players could be linked mechanistically.
Important is that even in young familial AD-cases,
amyloid pathology is always accompanied by Tau pathology,
similar to late sporadic cases of AD. This establishes tauo-
pathy even more ﬁrmly as cause, besides or rather than
codiagnostic hallmark in all AD cases! Scientiﬁc reasoning
takesthisonestepfurther,toimplicatetauopathyinthemore
early stages of AD, conform to the origin of pathology in
primary tauopathies. Important caveat here is that the early
stages of Tau pathology are yet to be deﬁned molecularly in
humanpatients.Thiswasandremainsaformidablescientiﬁc
challenge: biochemical and biophysical deﬁnition of the
neurotoxic Tau species, which we have termed Tau-P∗ [19].
2.ProteinTau:Physiology andPathology,
anUnstable Balance
In contrast to the apparent redundancy of the physiological
function of protein Tau, as demonstrated in Tau-deﬁcient
mice [20], the presumed pathological importance of protein
Tau was established by the discovery of inherited mutations
in the MAPT gene. These are tightly linked to the disease
in families suﬀering autosomal dominant frontotemporal
dementia with parkinsonism linked to chromosome 17
(FTDP-17) [21–24]. Once more, genetic ﬁndings established
a key factor in the pathogenesis of a disease, in this case pro-
tein Tau in a subgroup of FTD, a heterogeneous group of
tauopathies characterized by dementia and movement dis-
orders.
The structure of the Tau gene has been reviewed in detail
elsewhere [25, 26]. Alternative mRNA splicing of exon 10,
encoding the second of four microtubule-binding domains
(MTBD) produces two major isoforms, denoted as Tau.3R
and Tau.4R, respectively, with lower and higher aﬃnity for
microtubules (MT) [27–29]. The abundance of Tau.3R and
Tau.4R in human brain changes during brain development
and neuronal diﬀerentiation. In embryonic brain, Tau.3R
isoforms dominate, apparently providing structural and
morphological plasticity to developing and diﬀerentiating
neurons. In mature neurons, Tau.4R gains importance and
b e c o m e sl a r g e l yl o c a t e di na x o n s ,e x c l u d e df r o ms o m aa n d
dendrites where other MAPs predominate. In the adult
human brain, Tau.3R and Tau.4R isoforms are balanced,
while in adult mouse brain the Tau.4R isoforms prevail
[30, 31].
Importantly, both intronic and exonic mutations in the
MAPT gene are associated with FTDP-17. Many are located
in exon 10 or in the surrounding introns, aﬀecting the alter-
native splicing of this exon. Evidently, intronic mutations
produce normal, wild-type proteins, which in case of pro-
tein Tau result in the distortion of the normal isoform-
balance.AnabnormalTau.3R/4Rbalance,eitherincreasedor
decreased, is thought to disturb the function of Tau in MT
assembly, stabilization, and transport. Expressed mutations
then are presumed to provoke similar problems, while
mutant Tau in general is more prone to phosphorylation and
polymerization [27–29].
Immunohistochemical and biochemical studies, sup-
ported by genetic data, have revealed that in speciﬁed tauo-
pathies the pathology directly reﬂects the aberrant Tau iso-
form ratio. For instance, in PSP, CBD, and AGD, the inclu-
sions contain mainly Tau.4R isoforms [30, 32, 33], whereas
Pick bodies contain mostly Tau.3R. Furthermore, in familial
FTD, exonic mutations, for example, P301L, P301S, G272V,
N279K, V337M, R406, cause signiﬁcant overrepresentation
of Tau4R [34, 35]. In AD and other tauopathies, variable ad-
mixtures of the two major Tau isoforms are biochemically
detected in aggregates and deposits in soma, dendrites, and
axons. Obviously, an inconsistent picture emerges of Tau
isoformsbiochemicallyassociatedwithdiﬀerenttauopathies,
although all are pathologically deﬁned by argyrophilic tauo-
pathy.
Our eventual molecular understanding of the role played
by abnormal structural features of protein Tau in human
tauopathies must ultimately be based on the knowledge of its
normal cellular functions. The major, and as far as we know,
only physiological function of protein Tau involves its capac-
ity to bind to microtubules to control or aﬀect spacing, stabi-
lization and dynamics [36–38]. That protein Tau is involved
in signal transduction, neuronal diﬀerentiation, organello-
genesisandgrowthcanlikelybereducedtothesameprimary
actofMT-binding[39–41].WewillnotindulgeindescribingInternational Journal of Alzheimer’s Disease 3
the processes in which protein Tau has been implicated or
proposed, a subject reviewed recently elsewhere [42].
The function of Tau in adult—and ageing—brain is
supposed to be ﬁne-tuned by post-translational mechanisms
besides the alternative mRNA splicing producing Tau.3R and
Tau.4R isoforms. The prime one is phosphorylation of a
limited set of serine and threonine residues, selected among
the 79 available. With respect to the mechanism governing
this selection, one must not only consider the speciﬁcity of
diﬀerent kinases responsible, but also the naturally unfolded
nature of protein tau, which presumably exposes most, if not
all the S/T residues.
3. Phosphorylation, Missorting, and
Aggregation: In What Order andExtent?
Over the last years, following and thanks to the genetic dis-
coveries in the MAPT gene, striking observations in patients
but mainly in experimental models have changed some
long-established convictions concerning the role of protein
Tau in cognitive disorders and neurodegeneration.
In transgenic mice, regulated expression and suppres-
sion of mutant protein Tau correlated with defective and
improved cognition [43]. Moreover, protein Tau but not
NFT appeared involved in neuronal death in transgenic mice
and AD patients [44, 45]. Elimination of protein Tau in
an amyloid mouse model restored cognitive and behavioral
deﬁcits [46], corroborating observations in AD patients that
tauopathy deﬁnes the cognitive demise, discussed above.
Moreover, not APP but protein Tau proved neurotoxic for
pyramidal neurons in CA1 and cortex in a nontransgenic,
AAV-based model, with formation of oligomeric but not
ﬁbrillar Tau [47].
I d e a st h a th a v eb e e ns i m m e r i n gf o ry e a r sa r em o r ea n d
more substantiating that speciﬁed neuronal dysfunctions are
evident before NFTs are deposited. Moreover, the synapto-
and neurotoxicity of protein Tau depends on its posttrans-
lational modiﬁcations, in ﬁrst instance O-phosphorylation,
but also others that need to be explored in detail: Y-phos-
phorylation, glycation, glycosylation, acetylation, sumoyla-
tion, among others [48–52]. Therefore, accurate temporal
and spatial patterns of pathological traits that must also
be physiologically important deserve investigation to under-
stand their role in the genesis and evolution of AD and
tauopathies.
In general, increased phosphorylation of protein Tau
decreasesitsbinding to MTandthereby regulatesthenormal
biological activity of protein Tau related to microtubule
spacing, assembly and stability. Obviously, phosphorylation
ofproteinTauispartofnormalphysiologicalregulatorypro-
cesses and not pathogenic per se [39, 53]. Conversely, in AD
and all primary tauopathies, protein Tau becomes more and
more phosphorylated with disease progression, to enter a
state that is generally referred to as “hyper-phosphorylated.”
Nevertheless, no exact lower or upper limits are deﬁned to
this connotation, which exposes a major molecular and ana-
lytical problem: how many of the vast number of potential
O-phosphorylation sites in protein Tau are physiologically
relevant? In second order, the question is, are these sites
directly pathologically implicated—or merely correlated? We
currently address these questions by “timeline” analysis of
transgenic mouse brain to deﬁne which phosphorylation
levels and sites generate or accelerate disease.
While several studies suggest that the functional impact
of phosphorylation depends on the speciﬁc phosphoryla-
tion sites [54–56], others support the notion that overall
increased, not site-speciﬁc, phosphorylation is suﬃcient
[57]. It is well-known that in development and postnatally,
protein Tau is heavily phosphorylated. This “fetal Tau” binds
less to MT and helps maintain dynamics of microtubule
assembly/disassembly during this period of most active
neurite outgrowth, albeit without eliciting tauopathy or
neurotoxicity as in ageing brain. Diﬀerentiating functional
diﬀerences between normal Tau in the immature brain and
pathological Tau in ageing brain might deﬁne phosphoryla-
tion of Tau at some speciﬁc sites, for example, S199, T231,
and S396 in AD brain [58].
Tau phosphorylation is markedly increased in response
to various stressors. Phosphorylation, although to lesser lev-
els than in AD brain, appears to be mobilized by neurons to
regulate activity of Tau transiently and reversibly as required.
A prime example is hibernation as adaptive process that rep-
resents a powerful physiological strategy to withstand peri-
odsoflimitedenergysupply.Hibernationisahypometabolic
state with declining body temperature, periodically inter-
rupted by brief spontaneous periods of rewarming to core
temperatures, whereby selective expression and control of
kinases and phosphatases is an adaptive response for long-
term survival [59]. Highly phosphorylated protein Tau
readilyaccumulatesandevenappearstoaggregateinbrainof
hibernating animals, while most interestingly the entire pro-
cess is fully reversed when animals arouse, restoring normal
temperature and metabolism without harming neurons or
networks [60–62].
Other conditions, associated with reduced body temper-
ature and increased Tau phosphorylation are starvation [63],
cold water stress [64], and anesthesia [65]. Several reports
suggest that anesthesia-induced hypothermia increases the
risk of AD [66, 67]. Temperature ﬂuctuations aﬀect the
relative balance of kinase and phosphatase activity [65, 68].
In a mouse model with incipient neuroﬁbrillary pathology,
the pool of free hyperphosphorylated Tau was recruited into
Tau aggregates that accumulate over time [69]. Moreover,
isoﬂurane anesthesia in young Tau.P301L transgenic mice
provokes brainstem tauopathy and upper airway defects,
suggesting similar problems in elderly patients exposed to
anesthetics for surgery [70].
4.TauKinases:GSK3Accepted,
Others Explored...
The GSK3 kinases appeal as candidates to modulate Tau
phosphorylation for several reasons: (i) they are abundantly
expressed in neurons, (ii) their levels and/or enzymatic
activity is increased in AD brain [71, 72], and (iii) they can
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also phosphorylated in AD brain, that is, S199, T231, and
S396 [73–75]. Additionally, in our transgenic Tau mouse
models, GSK3 greatly increased the severity of tauopathy
when expressed in conjunction with mutant Tau.P301L [76,
77], but alleviated the axonopathy when coexpressed with
wild-type Tau.4R [78]. Moreover, and surprising for a nat-
urally unfolded protein is the notion that phosphorylation
aﬀects the conformation of protein Tau. Monomeric Tau
in solution, when phosphorylated at critical sites either
upstream or downstream of the MTBD, appeared to adopt
a more compact conformation that was proposed to reﬂect
its propensity to aggregate [79].
The long-standing deﬁnition of protein Tau as an axonal
protein, and even axonal marker [80, 81], contrasts with
the early pathological defects observed in most tauopathies:
abnormal delocalization into the somatodendritic compart-
ment where protein Tau becomes even more phosphorylated
and subsequently forms the well-known aggregates and
NFT. Several hypotheses for the axon-speciﬁc location were
proposed: axon-speciﬁc sorting of mRNA coding for protein
Tau or preferential degradation of mRNA and/or protein
Tau in dendrites, aﬀected or even steered by selective phos-
phorylation of protein Tau [82–84]. In the last years, among
eﬀorts to clarify these issues a new proposal for a retrograde
ﬁltering action dependent on microtubules would allow pro-
tein Tau to move into but not out of axons [85]. Moreover,
once protein Tau becomes phosphorylated, its microtubular
interaction is decreased or disrupted, and phospho-Tau can
bypass that barrier. A diﬀerent mechanism depends on the
activation of the PAR-1/MARK kinase to phosphorylate
protein Tau downstream of signaling initiated by amyloid
[86], thereby contributing to relocate protein Tau. This
would explain its eﬀects on synaptic traﬃcking, anchoring
of glutamate receptors, and interaction with other kinases in
disturbing postsynaptic functions [40, 87].
5.The Neurotoxic Species,
Known Only as Tau-P∗
Intracellular aggregation and deposition of protein Tau as
N F Ti ns o m aa n dp r o c e s s e si sc o m m o n l yo b s e r v e di na l l
tauopathies, including AD. These aggregates, predominantly
composed of highly phosphorylated protein Tau, are deter-
gent insoluble and presented either as paired helical ﬁla-
ments (PHF), twisted ribbons, or straight ﬁlaments, usually
in varying combinations. Although the load of NFT corre-
lates with the severity of cognitive impairment in humans,
mouse models for tauopathy demonstrate memory defects
to precede NFT-like tauopathy [19, 77, 88, 89]. Moreover,
in a conditional model, reversal of Tau expression reversed
the cognitive defects even without aﬀecting the Tau deposits
[43, 90]. The levels of early multimeric Tau-aggregates that
preceded the NFT were found to correlate with memory
deﬁcits [91]. These ﬁndings corroborate the hypothesis that
molecularly unspeciﬁed intermediates in the Tau-aggrega-
tioncascade,situatedbetweensingleTaumoleculesandlarge
ﬁbrils, are the actual neurotoxic agents. The connotation
Tau-P∗,a sd e ﬁ n e dp r e v i o u s l y[ 19, 92], represents interme-
diate forms of phosphorylated protein Tau, which remain
to be deﬁned molecularly. They are proposed to adopt
a transitional conformation state and to be the eﬀective exe-
cutersofsynapticandeventuallyneuronaltoxicity,iforwhen
they are not directed into formation of the large ﬁbrillar
Tau-aggregates that we now consider not or less harmful
for neurons. Therefore, decoding the sequence of events that
transform soluble or MT-bound Tau into a toxic molecular
intermediate that only later becomes an inert aggregate is the
key to understand ontogenesis and evolution of any tauo-
pathy. In addition, these studies entertain the idea that ther-
apeutic intervention is possible by acting on the expression,
phosphorylation, and aggregation of protein Tau.
The formation of NFT involves sequential steps as
studied best with recombinant proteins in vitro and, because
cellular models are still lacking, are corroborated by the
timelineofeventsintransgenicmousebraininvivo[93].The
ﬁrst step is believed to be the neutralization of the protein
Tau-microtubuleinteractionbyphosphorylationbydiﬀerent
kinases,increasingthecytoplasmiclevelsofunboundprotein
Tau. Moreover, while protein Tau lacks a well-deﬁned struc-
ture, the initial phosphorylation promotes an unspeciﬁed
molecular state that appears favorable for dimerization and
aggregation [79, 94]. The adopted presumed β-sheet struc-
ture involves the MTBD of protein Tau, whereby eventual
disulﬁde bridging, although not generally accepted, could
help shift the equilibrium from soluble monomers to higher-
order multimers [95, 96]. Subsequently, further association
of β-ﬁbrillar Tau-multimers leads to ﬁlaments that deposit
as neuropil threads and tangles in the soma.
Biochemical indices for the occurrence of oligomers were
interpreted to represent oﬀ-pathway aggregates that do not
form ﬁlaments [97]. Whether or not hyperphosphorylation
of protein Tau is an indispensable event for the initial
dimerization remains elusive and debated. In vitro studies
demonstrated that ﬁbrillar assemblies of protein Tau are not
per se phosphorylation dependent [74] and even that the
propensity of protein Tau to form multimers is reduced by
phosphorylation particularly of S262 by MARK2/Par1 [98].
Moreover, even the inverse order of events was demonstrated
inamousemodelforaggregationofproteinTau,becausethe
incipient aggregation was the actual trigger for subsequent
phosphorylation of protein Tau [99]. Consequently, deﬁning
the molecular identity of the intermediate Tau species
referred to as Tau-P∗, a hyperphosphorylated, conforma-
tional small aggregate, will be a major step forward on the
arduous route to the most appropriate therapeutic target in
AD, and in primary tauopathies.
6. Brain-Regional Propagationof Tauopathy
Anatomical patterns of the pathology in human brain sug-
gest, but do not prove, a progressive spreading of tauopathy
with progressing cognitive decline [100]. Initial depositions
of phosphorylated protein Tau are ﬁrst observed in the locus
coeruleus, one of several subcortical nonthalamic nuclei that
has diﬀuse projection to the cortex. Subsequently, immuno-
chemical deﬁned phosphorylated protein Tau is observed
in entorhinal cortex and in its eﬀerent hippocampal and
neocortical regions [101].International Journal of Alzheimer’s Disease 5
This apparent spreading of the tauopathy throughout
human brain in a speciﬁed regional pattern has been the
subject of various hypotheses. Initial evidence for cell-to-
cell transfer of protein Tau aggregates came from two studies
carried out in cells and in vivo. The ﬁrst demonstrated that
ﬁbrilsofproteinTauaddedtotheculturemediumweretaken
up by neuronal cells and caused formation of Tau-aggregates
in the cytoplasm [102]. The second reported that in mouse
models of tauopathy, intracerebral injection of brain tissue
extracts containing Tau-aggregates initiated spreading of
intracellular Tau-aggregation from the injection site to other
brain areas, although not producing neurodegeneration
[103]. These experimental studies still remain controversial
and need to be conﬁrmed, eventually to deﬁne the route and
mechanism whereby cytoplasmic aggregates of protein Tau
can become secreted and taken up by neurons, in order to
establish the transmittance between neurons as a potential
mechanism of spreading of tauopathy in human brain [104].
Most recent data from novel mouse models that express
Tau.P301L speciﬁcally and only in the entorhinal cortex
(ERC) corroborate the hypothesis of cell-to-cell spreading of
tauopathy, but leaves the responsible mechanisms open for
speculation [105, 106].
7 .M o us eM od el sf o rT auP at h o l ogy
TounderstandtheimpactofTauphosphorylationandaggre-
gation in synaptic and neuronal degeneration, fully char-
acterized mouse models that exhibit the typical phenotypic
features and pathological changes of human tauopathies are
needed. Many transgenic mouse models for tauopathy have
been developed and characterized over the last decade and
were the subject of some recent reviews [19, 88, 107]. Here,
we limit the discussion to our mouse models that represent
or recapitulate interesting aspects of the pathology of protein
Tau in Tau pathologies, including AD.
7.1. Tau.4R Mice. They express full length, wild-type human
Tau under control of the mouse Thy-1 gene promoter in
the FVB/N genetic background. The advantage of the mouse
Thy-1 gene promoter permits neuron-speciﬁc expression of
the transgene, which begins in the second week postna-
tally, avoiding interference with development. Tau.4R mice
present increased phosphorylation of human protein Tau,
however without formation of any Tau-aggregates even at
late age [108]. Conversely, Tau.4R mice develop axonopathy,
initially consisting ﬁrst of axonal dilatations or spheroids,
evolving into Wallerian degeneration with muscle wasting.
The evident motor problems, already present at young age
(6 weeks) in homozygous Tau.4R mice, are explained by
excessive binding of protein Tau.4R to microtubules. This
prevents the normal binding and passage of motor proteins
responsible for axonal transport in both directions, resulting
in the stochastic accumulation of transported items, from
synaptic vesicles to mitochondria over Tau and neuroﬁla-
ment aggregates [108].
Remarkably, the severe axonopathy and motor prob-
lems hardly aﬀect the survival of the Tau.4R mice [89, 108].
Moreover, the pathological phenotype was rescued by coex-
pression of GSK3β, resulting in bigenic mice that appear
largely normal [78]. Molecularly, this is explained by the
evident increased phosphorylation by GSK3β of human
proteinTau.4R,whichdisplacesitfromthemicrotubulesand
thereby restores normal axonal transport in both directions.
Despite the fact that protein Tau.4R became highly phospho-
rylated in brain of the Tau.4RxGSK3β bigenic mice, no Tau
pathology resulted. Besides demonstrating for the ﬁrst time
in vivo that GSK3β is an eﬀective Tau-kinase, the data also
underlined that additional phosphorylation by other kinases
is needed to develop tauopathy. A ﬁnal argument explaining
the lack of tauopathy in Tau.4R mice, and by extension in
thebigenicTau.4RxGSK3βmice,wasourmostrecentﬁnding
of the strict axonal location of Tau.4R, as opposed to the
somatodendritic delocalization of Tau.P301L in transgenic
mouse brain [92, 109].
7.2. Tau.P301L Mice. In contrast to Tau.4R mice they exhibit
less extensive phosphorylation of mutant protein Tau at
younger age, but nevertheless develop into a representative
modeloftauopathywithneuroﬁbrillarytanglesandneuropil
threads at older ages. These mice express the well-known
human mutant Tau.P301L, the ﬁrst to be associated with
FTDP-17 [22, 23]. Human Tau.P301L is homozygously
expressed under control of the same mouse Thy-1 gene
promoter and in the same FvB/N genetic background as the
Tau.4R mice [89].
Phosphorylation of Tau.P301L in mouse brain is initially
low even up to the age of 7 months at the epitopes deﬁned by
Mabs AT8 and AT180, although phosphorylation is detect-
ablewithprobesAD2andAT270[89].Thediseaseassociated
epitope AT100 was even completely absent at young age.
In older Tau.P301L mice, phosphorylation of Tau increases
leading to reduced aﬃnity of the MT-binding and conse-
quent delocation to soma and dendrites. The local aggrega-
tion into tangles and neuropil threads in terminal mice is
demonstrated immunohistochemically with Mab AT100 and
others, for example, MC1 and PHF1, and biochemically by
hyperphosphorylated Tau in the sarkosyl-insoluble fraction
(Figure 1)[ 89]. The development of the tauopathy becomes
associated with motor problems, illustrated by clasping and
rotarodperformanceevenasearlyasage7.5months,because
the hindbrain and particularly speciﬁed nuclei in the brain-
stem, for example, Koelliker-Fuse and raphe, are hit by the
tauopathy.
Most recently, we discovered the associated reduction of
involuntary control of breathing, resulting in upper-airway
defects that cause excessive workload of the diaphragm,
leading to impaired ultrasonic vocalization, exhaustion, and
asphyxia, most likely associated with dysphagia in old mice.
These defects then explain the clinical moribund phenotype
of terminal Tau.P301L mice, with dramatic reductions in
bodyweight: males drop below 20–18 grams, females below
16 grams. Premature death occurs mainly in the time-
window of 8–10 months with the mean around age 9.4
months, not dependent on gender, and with practically no
survivors beyond age 12 months. The terminal stage evolves6 International Journal of Alzheimer’s Disease
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Figure 1: Selected biochemical and pathological characteristics of transgenic mouse models. (a) Soluble and sarkosyl insoluble fractions of
Tau (SInT) were isolated as described [10] and proteins separated by SDS-PAGE on 10% tris-glycine gels. After transfer to nitrocellulose
membranes, proteins were immunoblotted with either anti-pS396 (Invitrogen, Carlsbad, CA) or HT7 (Innogenetics, Gent, Belgium).
Phosphorylated human Tau (apparent Mr about 64kDa) is evident in soluble fractions from forebrain and brainstem of all three genotypes.
SInT is evident in forebrain and brainstem of terminal TPLH and old biAT mice (age 15 months) but not in the brainstem of old biGT mice
(15 months). (b) Immunohistochemistry with AT100 on free-ﬂoating sagittal sections of terminal mice shows tangles and neuropil threads
in cortex and brainstem of all genotypes, but signiﬁcantly less in the brainstem of biGT mice. Tauopathy is minimal or absent in pyramidal
neurons of the hippocampus of terminal Tau.P301L transgenic mice.International Journal of Alzheimer’s Disease 7
aggressively and takes less than 2-3 weeks after the ﬁrst signs
of motor impairment, whereby the mice rapidly lose body-
weight, display a dystonic posture with progressive paralysis
of all limbs and associated breathing problems leading to
asphyxia, the presumed cause of premature death [11, 89,
110, 111].
Unexpectedly, the cognition of young Tau.P301L mice
was markedly better than that of wild-type mice, with ame-
liorated long-term potentiation in the dentate gyrus and
improved cognitive performance in object recognition tests
[112]. This was anatomically substantiated by higher levels
of mature spines in hippocampus and cortex compared to
wild-type mice [109]. Although the spine maturation ratio
remained high in hippocampus of adult Tau.P301L mice, the
spines regress in length paralleling the impaired cognition,
the increased phosphorylation and relocation of protein
Tau.P301L from axons to soma and neuritic processes [109,
112].
Tau.P301Lmice do not suﬀerany amyloid pathology and
do not stand as a model for AD pathology, but these mono-
genic mice are an excellent model to study the impact of
hyperphosphorylation and aggregation of protein Tau in dif-
ferent Tau pathologies. The progressive impairment that we
documented in the Tau.P301L mice, starting from defective
learning and memory in adults to problems at later age
withbreathingandvocalization,swallowing,movement,and
motor defects, Tau phosphorylation, and aggregation into
tangles, all correspond with features known from human
tauopathiesandneurodegenerativediseases.Needlesstostate
that the eﬀect of drugs or disease modifying treatments that
target the pathological Tau, or its downstream partners or
sequellae, can be evaluated in the monogenic Tau.P301L
mice [19, 113].
7.3. biAT and biGT Mice. To deﬁne the relations and syn-
ergism between amyloid and Tau pathology in AD, and of
the role of the GSK3 kinases, double transgenic mice were
developed by combining homozygous Tau.P301L mice
with either heterozygous human GSK3β.[S9A] mice or
APP.V717I mice [77, 78, 114, 115], resulting, respectively,
in GSK3βxTau.P301L (biGT) and APP.V717IxTau.P301L
(biAT) bigenic mice. In both strains, the Tau pathology is
aggravated with ageing by progressively increasing phos-
phorylation of Tau.P301L at typical pathological and con-
formational epitopes, resulting in the formation of highly
ﬁbrillary tangles and threads in cortex and hippocampus
[77]. Conversely, in the brainstem of biGT mice the Tau
pathology was signiﬁcantly reduced relative to that in the
parentalTau.P301Lmice,whichcorrelateswiththemarkedly
prolonged survival of the biGT mice compared to Tau.P301L
mice: IC50 of 13 months versus 9.3 months, respectively.
Originally,weobservedanddescribedprolongedsurvival
of the biAT mice, which was explained, by the increased
activation of both GSK3 isozymes, that is, increased tyrosine
phosphorylation,apparentlydrivenbythehighamyloidbur-
den,asit wasobserved in theparental monogenic APP.V717I
mice [77]. The subsequent in-depth further characterization
of the biAT mice revealed a more complex pattern of
mortality,whichwillbereportedindetailelsewhere[116].In
brief, young biAT mice are prone to spontaneous or evoked
epileptic seizures that cause a signiﬁcant premature death in
the tile-window of 1–6 months. Mortality is thereby evident
at younger age and more frequent than in the parental
APP.V717I mice [117].
Thereafter, mortality subsides, with a sizable fraction of
biAT mice, particularly females surviving longer than the
parental Tau.P301L mice. Of note, the female survivors
develop,moreseverelythanmales,thetypicalcombinedAD-
related pathology in relevant brain regions, that is, hip-
pocampus, neocortex, entorhinal cortex, piriform cortex,
and amygdala [77, 115]. In the forebrain of surviving biAT
mice, the amyloid pathology with intracellular vesicular
amyloid, extracellular diﬀuse and senile plaques, and vascu-
lar amyloid sets in at age from 10 to 12 months, preceding
the Tau pathology. Of note, intracellular vesicular amyloid
accumulation is already evident at young age (4–6 months)
andisaccompaniedbyincreasedphosphorylationofendoge-
nous mouse Tau and of human Tau.P301L at the AT8 site.
The timing remarkably coincides with the activation of the
GSK3 kinases by intramolecular tyrosine phosphorylation
and with the hippocampus-dependent cognitive deﬁcits of
APP.V717I and biAT mice. Cognition is already impaired at
young adult age (age 4–6 months), well before the onset of
amyloid deposition or Tau pathology, sensu stricto. Young
adultbiATmiceareseverelyimpairedeveninlessdemanding
tests, that is, novel object recognition, passive inhibitory
avoidance, and conditioned taste aversion [77].
S i m i l a rt oh u m a n ss u ﬀering progressive senile types of
dementia, ageing severely impacts the clinical phenotype of
the bigenic mice, particularly of the biAT mice with pro-
gressive reduction in body weight, loss of ambulation, and
reducedfurcondition followingthemoreearlycognitive and
behavioral impairments. The comparative evolution in both
bigenic strains with ageing point to comparative underlying
mechanisms, adding support to the hypothesis that amyloid
triggers the tauopathy by increasing GSK3 activity [77, 118,
119].
8. Hypothesis:Tau, Phospho-Tau,
Tau-P∗, Oligomers, Fibrils, andTangles
“...as t a g e ,a n da l lt h e ...merely players”
W. Shakespeare 1598.
The molecular characterization of protein species inter-
mediate between the monomers prepared by biochemists
andthelargeﬁbrilsobservedpostmortembythepathologists
is a hot topic in current neuroscience research and for many
proteins that are proven or surmised to be implicated in
neurodegenerative disorder [15, 120–123]. Probably, amy-
loid is the most advanced in this respect, although no single
intermediate Aβ-oligomer is yet accepted as the only or even
major toxic species. Relying on thermodynamics and mass-
action laws, one can even predict that a single species will
never be identiﬁed as the proven cause of all the distress in
AD brain over a period of 20 years, or more.8 International Journal of Alzheimer’s Disease
Dementia
APP
Early stages
NFT  
pY-GSK3
pTau  
Amyloid pathology
MCI
(Aβ)n
Neurotoxic
Tau-MT
X-kinases Mark2/Par1
X-kinases
Tau-P∗
Synaptotoxic
Figure 2: Schematic view of relations between amyloid and Tau in Alzheimer’s disease. The interpretation hinges on the concept that the
production of the Tau-P∗ intermediates are the central molecular species in the overall process. The incorporation of GSK3 as a major
coupling link between the two pathologies is underscored essentially by in vivo observations in the mono- and bigenic mouse models
discussed in the text. Protein Tau is a very soluble, naturally unfolded protein that in physiological conditions is located mainly in axons and
attachedtomicrotubules,denotedasTau-MT.ActivationbyamyloidofbothGSK3kinases,togetherwithotherkinasesincludingMar2/Par1,
gradually transforms Tau-MT into a pool of soluble, phosphorylated Tau (pTau) in the cytoplasm. Because of their delocalization, the pTau
species undergo further posttranslational modiﬁcations, mainly including additional phosphorylation but eventually also nitrosylation,
acetylation,truncation,allcausingthetransitionintotheconformationalproteinTauspeciesthatwepreviouslydenotedasTau-P∗ [11].This
as yet molecularly undeﬁned intermediate likely represents soluble low-order aggregates that cause the early synaptic defects and cognitive
problems typical for all tauopathies, with brain-region speciﬁcity as discussed in the text. The escape of Tau-P∗ from normal elimination
via the proteasome and/or by autophagy leads to its accumulation, which by mass-action results in aggregation into NFT. We primarily
consider NFT not to be detrimental for neurons, and initially they can even constitute a relative safety measure, as they reduce the free levels
of Tau-P∗ and thereby its negative actions. Conversely, in the long term, the progressive accumulation of Tau-P∗ into more NFT deposition
in neuropil and soma must invoke negative eﬀects and eventually result in axonal and dendritic defects that culminate in neurodegeneration.
This process is schematically reﬂected by the green-to-red color gradient of the background of the NFT box in the scheme.
Pathological and experimental evidence increasingly
questions the direct link between intraneuronal accumu-
lation of Tau-aggregates and the neuronal degeneration
observed in the later phases of dementia.
Many neurons that accumulate NFT in aged human
brain and in transgenic mouse brain are not marked by char-
acteristic morphological signs of cellular death. Conversely,
many neurons that do bear such markers do not appear to
have a signiﬁcant load of high-order Tau ﬁlaments [44, 124].
Therefore, both tangle formation and neuron loss should
be considered as dissociated processes, at least in time,
but likely also in actual underlying mechanisms (Figure 2).
Direct assessment of the relation of tangles and neuronal
function by electrophysiology of individual neurons ex vivo,
concomitant with structural analysis of dendritic branching
and spines, did not correlate with NFT bearing [125]. Simi-
larly,theﬁndingsinmammalianmodelswasalsoobservedin
invertebrate Tau models [126, 127]. The justiﬁed conclusion
must be that other, less aggregated or even soluble forms
of protein Tau are responsible for neuronal dysfunction and
by extension for failing synaptic plasticity and cognition.
More and more, NFTs are regarded to function as the intra-
neuronal sink for excess phosphorylated protein Tau that
was released from the axonal microtubules and after delo-
calization and extra phosphorylation is unable to regain
its normal physiological position and function. By forming
large ﬁbrillar aggregates, neurons are protected from toxic
eﬀectsofsoluble,smalleraggregates[128,129],amechanism
that was even proposed as a potential therapeutic approach
[130]. Obviously, the cytoplasmic sink is limited in capacity
and this protective measure cannot but be limited in time,
eventually resulting in the damage and death of the neuron,
exempliﬁedbythepresenceofghosttanglesinthelaterstages
of tauopathy [16].
Tau species responsible for cognitive dysfunction were
tentatively identiﬁed as multimers of apparent Mr 170kDa,
present in FTD and AD brain, and correlating with memory
index and motor deﬁcits in tauopathy models [91]. Fur-
thermore, Tau oligomers prepared with Aβ oligomers as
initial seed invoked memory impairment and synaptic and
mitochondrial dysfunction in wild-type mice [131]. Inverte-
bratetransgenicmodels,forexample,drosophilathatexpress
wild-type or mutant Tau isoforms also concluded to soluble
cytosolic Tau species as accountable for toxicity [48, 132].
Conversely, our own experiments with AAV-based vec-
tors in wild-type mice revealed early damage mainly to
dendrites by human wild-type and mutant Tau alike, accom-
panied by extensive phosphorylation and smaller Tau-aggre-
gatesofTau,butwithoutformationoflargerﬁbrils[47,133].
The situation led us to postulate that a phosphorylated
intermediate, most likely a dimer or small aggregate that we
termed Tau-P∗, is responsible for cognitive dysfunction byInternational Journal of Alzheimer’s Disease 9
synaptic toxicity [19]. Our hypothesis hinges on the concept
that the production of Tau-P∗ molecules constitutes for the
neuron the tipping-point of whether or not to form the
protective large aggregates. If for some reason, this is not
possible, the accumulation of Tau-P∗ molecules will damage
the neuron and impair synaptic function and plasticity,
causing cognitive dysfunction (Figure 2).
This concept incorporates diﬀerent signaling mechanism
hinging on GSK3, and without abandoning the amyloid
hypothesis. In the light of in vivo observations in transgenic
mice, discussed in the foregoing sections, we maintain the
GSK3 kinases center-stage as important link between the two
pathologiesinAD,reconcilingtheamyloidandTaudoctrines
[77, 92, 119]. Activation of both GSK3 kinases by aberrant
Aβ production and/or APP processing [134] is not the pri-
mary cause of the disease, but a major link to turn on the
phosphorylation-cascade of protein Tau and the formation
of Tau-P∗ intermediates. We realize that one kinase cannot
suit all the known phosphorylation sites on protein Tau,
whilealsothetransformationofTau-P∗ toNFTmustdepend
on unknown factors (Figure 2). Moreover, the relation to the
early and late cognitive impairment must depend on a host
ofasyetunknownmolecularfactors,termedX-factorsbefore
[19, 113] that must be held liable for the clinical symptoms
in AD. Diﬀerent factors in diﬀerent individuals are expected
tohelpexplainthevariableonsetandevolution,aswellasthe
variable cognitive and behavioral symptoms despite similar,
although also variable brain pathology.
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